Michael Makris/LinkedIn
Dec 18, 2025, 23:25
Michael Makris: Excellent Article in This Week’s NEJM Explains Word Estimand Clearly
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Do you know what is an “estimand”?
I had never heard of the word until today, but this excellent article in this week’s New England Journal of Medicine (NEJM) explains it clearly.
Essentially, it is the effect of actually taking a drug in a randomised trial. Although simplistically attractive there are good reasons why Intention to Treat (ITT) analysis should remain the gold standard. I can see estimands being used increasingly by manufacturers and sponsored speakers at meetings.”
Discover the latest in Hemostasis Today.
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Grateful to Be Connecting with so Many Families and Advocates at HFA 2026 in New Orleans
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA